 SAN FRANCISCO, June 21, 2022 GLOBE NEWSWIRE -- 89bio, Inc. Nasdaq: ETNB, a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced additional pegozafermin data in non-alcoholic steatohepatitis NASH will be presented at the European Association for the Study of the Liver EASL International Liver CongressTM 2022, to be held in London, UK on June 22-26, 2022. 